9月医药BD交易密集披露:创新药与类似药出海并进,商业化兑现加速

澎湃新闻
Sep 29

即将过去的九月,中国医药行业BD(业务拓展)交易密集官宣。  9月29日,恒瑞医药(600276.SH,1276.HK)宣布,与诺和诺德就其研发的潜在每周一次口服GLP-1和GIP双受体激动剂HRS-1596达成合作。诺和诺德将获得该管线在大中华地区以外的全球独家权利。该交易潜在总额最高可达26亿美元,其中包括3亿美元的首付款。HRS-1596目前已在中国获准开展用于体重管理和2型糖尿病的一期...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10